RecruitingNot Applicable

rTMS for Apathy Clinical Trial

Canada10 participantsStarted 2023-02-09

Plain-language summary

Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * mild or major neurocognitive disorder OR mild behavioural impairment * Apathy for at least 4 weeks * Stable dose of medication (\>4 weeks) that may affect cognition or behaviour * Care partner who spends at least 10 hours a week with the subject Exclusion Criteria: * Current major depressive episode * Agitation, delusions, hallucination * Medical contraindications to rTMS * Currently taking an amphetamine product * Central nervous system abnormalities, Tourette's syndrome, or motor tics * Current participation in another clinical trial

What they're measuring

Neuropsychiatric Inventory-apathy

Timeframe: 2 weeks

Trial details

NCT IDNCT05561205

SponsorSunnybrook Health Sciences Centre

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-01

View on ClinicalTrials.gov More Alzheimer Disease trials